Clinical trial NCT02578849 - References

Parkinson´s Disease — Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia

Citation(s)

•   Ahlskog JE, Muenter MD
  Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001 May;16(3):448-58.
•   Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E
  Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003 Mar-Apr;24(2):197-211.
•   Buck K, Ferger B
  Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. Neuroscience. 2009 Mar 3;159(1):16-20. doi: 10.1016/j.neu
•   Fox SH, Lang AE, Brotchie JM
  Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov Disord. 2006 Oct;21(10):1578-94. Review.
•   Hawkes CH, Del Tredici K, Braak H
  A timeline for Parkinson's disease. Parkinsonism Relat Disord. 2010 Feb;16(2):79-84. doi: 10.1016/j.parkreldis.2009.08.007. Epub 2009 Oct 28. Review.
•   Jakobsen S, Pedersen K, Smith DF, Jensen SB, Munk OL, Cumming P
  Detection of alpha2-adrenergic receptors in brain of living pig with 11C-yohimbine. J Nucl Med. 2006 Dec;47(12):2008-15.
•   Landau AM, Dyve S, Jakobsen S, Alstrup AK, Gjedde A, Doudet DJ
  Acute Vagal Nerve Stimulation Lowers a2 Adrenoceptor Availability: Possible Mechanism of Therapeutic Action. Brain Stimul. 2015 Jul-Aug;8(4):702-7. doi: 10.1016/j.brs.2015.02.003. Epub 2015 F
•   Rascol O, Schelosky L
  123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord. 2009;24 Suppl 2:S732-41. doi: 10.1002/mds.22499. Review.
•   Sara SJ
  The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci. 2009 Mar;10(3):211-23. doi: 10.1038/nrn2573. Epub 2009 Feb 4. Review.
•   Schapira AH, Olanow CW
  Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol. 2008 Dec;64 Suppl 2:S47-55. doi: 10.1002/ana.21460.

Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia and Healthy Age Matched Controls; [11C]Yohimbine and [11C]MeNER PET

Details for clinical trial NCT02578849